BioCardia, Inc. (BCDA)

0.3762 -0.0178 (-4.52%) At close: 04:00PM EDT

BioCardia, Inc.

320 Soquel Way
Sunnyvale, CA 94085
United States
650 226 0120
https://www.biocardia.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Peter A. Altman Ph.D.	CEO, President & Director	515.51k	N/A	1967
Mr. David McClung	Chief Financial Officer	370.86k	N/A	1963
Mr. Edward M. Gillis	Senior Vice President of Devices	263.1k	N/A	1962

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

Corporate Governance

BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.